Coronavirus: Commission signs a third contract with BioNTech-Pfizer for an additional 1.8 billion doses

Today (20 May), the European Commission signed a third contract with the pharmaceutical companies BioNTech and Pfizer. It reserves an additional 1.8 billion doses on behalf of all EU member states, between end 2021 to 2023. It will allow for the purchase 900 million doses of the current vaccine and of a vaccine adapted to variants, with the option to purchase an additional 900 million doses.

The contract requires that the vaccine production is based in the EU and that essential components are sourced from the EU. It also stipulates that, from the start of the supply in 2022, the delivery to the EU is guaranteed. The possibility for member states to resell or donate doses to countries in need outside the EU or through the COVAX Facility has been reinforced, contributing to a global and fair access to the vaccine across the world.

European Commission President Ursula von der Leyen said: “With our signature, the contract with BioNTech-Pfizer is now in force, which is good news for our long term fight to protect European citizens against the virus and its variants!  BioNTech-Pfizer has been key in helping us deliver enough doses by July to vaccinate 70% of the adult population. With this new generation contract, production and delivery in the EU of up to 1.8 billion doses are guaranteed.  Potential contracts with other manufacturers will follow the same model, to the benefit of all.”

A press release is available here.

Share this article: